Literature DB >> 15522958

Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells.

Juyang Kim1, Woon S Choi, Soojin La, Jae-Hee Suh, Byoung-Sam Kim, Hong R Cho, Byoung S Kwon, Byungsuk Kwon.   

Abstract

4-1BB, a member of the tumor necrosis factor (TNF) receptor superfamily, is a costimulator for activated T cells. Previous studies have established that treatment with agonistic anti-4-BB monoclonal antibody (3H3) is effective in reversing the progression of spontaneous systemic lupus erythematosus. Its therapeutic effect is mediated by suppression of autoantibody production. In this report, we show that a single injection of 3H3 blocks chronic graft-versus-host disease (cGVHD) in the parent-into-F1 model. In particular, donor CD4+ T cells are rapidly eliminated from host spleens by activation-induced cell death after 4-1BB triggering. Since donor CD4+ T cells are required for the development of cGVHD, and 3H3-mediated inhibition of autoantibody production occurs without donor CD8+ T cells, 3H3 blocks cGVHD by preventing alloreactive donor CD4+ T cells from activating host B cells. Importantly, 3H3 treatment can reverse the progression of advanced cGVHD. Our findings indicate that agonistic anti-4-1BB monoclonal antibody has potential as an immunotherapeutic agent for preventing and treating cGVHD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522958     DOI: 10.1182/blood-2004-06-2080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation.

Authors:  Hye J Kim; Jong S Lee; Jung D Kim; Hee J Cha; Ahra Kim; Sun K Lee; Sang C Lee; Byoung S Kwon; Robert S Mittler; Hong R Cho; Byungsuk Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

Review 2.  CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses.

Authors:  Bhushan Dharmadhikari; Meihui Wu; Nur Sharalyn Abdullah; Sakthi Rajendran; Nur Diana Ishak; Emily Nickles; Zulkarnain Harfuddin; Herbert Schwarz
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

Review 3.  Dual immunoregulatory pathways of 4-1BB signaling.

Authors:  Dass S Vinay; Kiweon Cha; Byoung S Kwon
Journal:  J Mol Med (Berl)       Date:  2006-08-05       Impact factor: 4.599

Review 4.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 5.  Murine models of chronic graft-versus-host disease: insights and unresolved issues.

Authors:  Yu-Waye Chu; Ronald E Gress
Journal:  Biol Blood Marrow Transplant       Date:  2008-02-13       Impact factor: 5.742

6.  Roles of Host Nonhematopoietic Cells in Autoimmunity and Donor Cell Engraftment in Graft-versus-host Disease.

Authors:  Juyang Kim; Sohye Park; Hyun-A Kim; Daehee Jung; Hyun Ju Kim; Hye-Jeong Choi; Hong Rae Cho; Byungsuk Kwon
Journal:  Immune Netw       Date:  2010-04-30       Impact factor: 6.303

Review 7.  Advances in targeting cell surface signalling molecules for immune modulation.

Authors:  Sheng Yao; Yuwen Zhu; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

8.  Hypercostimulation through 4-1BB distorts homeostasis of immune cells.

Authors:  Seung-Woo Lee; Shahram Salek-Ardakani; Robert S Mittler; Michael Croft
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 9.  Immune regulation and control of regulatory T cells by OX40 and 4-1BB.

Authors:  Takanori So; Seung-Woo Lee; Michael Croft
Journal:  Cytokine Growth Factor Rev       Date:  2008-05-27       Impact factor: 7.638

10.  CD137-CD137 Ligand Interactions in Inflammation.

Authors:  Byungsuk Kwon
Journal:  Immune Netw       Date:  2009-06-30       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.